Cullinan Therapeutics, Inc.
Company Stats
- Market Cap
- $987.8M
- as of Sep 30, 2026
- Shares Outstanding
- 64.4M
- Free Float
- 37.6%
Income Statement
- Operating Income
- -$241.6M
- Net Income
- -$219.9M
- EBITDA
- -$241.3M
Cash Flow
- Free Cash Flow
- -$175.8M
- FCF Yield
- -17.8%
- Owner FCF Yield
- -21.4%
Balance Sheet
- Cash & Equivalents
- $88.3M
Returns & Capital
- SBC, 3Y Avg
- $34.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$175.8M | — |
| FY2024 | — | -$145.3M | — |
| FY2023 | — | -$134.5M | — |
| FY2022 | $0 | -$127.8M | — |
| FY2021 | $18.9M | -$43.4M | -229.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back